HOME > LATEST
LATEST
-
REGULATORY LDP Members Raise No Call for Tax Cuts, Fret Inflationary Impact on Medical Facilities: Fiscal Reform HQ
April 25, 2025
-
BUSINESS BMS Oncology VP Goto to Lead Argenx Japan
April 25, 2025
-
BUSINESS Gilead Files Trodelvy for HR+/HER2- Breast Cancer in Japan
April 25, 2025
-
REGULATORY Japan to Buttress Regulatory Communication Efforts for Drug Originators Overseas
April 25, 2025
-
BUSINESS Enhertu Filed for HER2 Positive Solid Tumors in Japan
April 25, 2025
-
BUSINESS Sanofi Looks to Join Top 3 in Japan Pharma Market by 2030
April 25, 2025
-
BUSINESS Meiji’s Rezurock Grabs Approval in Taiwan
April 25, 2025
-
REGULATORY “Time to Revise” Fee Premiums for Generic Use: Chuikyo Payer Rep
April 25, 2025
-
REGULATORY LDP Group Calls for Keeping Health Coverage for Pain Relief Patches
April 25, 2025
-
BUSINESS Novo Unveils 4 Billion Yen Investment in Japan Factory
April 24, 2025
-
ORGANIZATION US Tariffs Would Hinder Access to Innovative Drugs: JPMA President
April 24, 2025
-
REGULATORY MHLW to Present Estimate on Coverage Removal of OTC-Like Meds at 3-Party Talks
April 24, 2025
-
REGULATORY MOF’s Spring Debate Puts Special Focus on CEA, More Aggressive Re-Pricing Eyed
April 24, 2025
-
BUSINESS Japan Approves Spikevax’s Prefilled Syringe Version
April 24, 2025
-
REGULATORY Epkinly to Face Price Cuts under CEA Scheme
April 24, 2025
-
BUSINESS Takeda’s Japan Earnings Bottomed Out, Now on Pace to Growth from FY2025: Head
April 23, 2025
-
BUSINESS BeiGene Sees Better-than-Expected Uptake for Brukinsa after March Launch
April 23, 2025
-
BUSINESS CSL to Join Forces with Specialists to Raise Awareness of HAE: Japan President
April 23, 2025
-
BUSINESS Fujifilm CDMO Strikes US$3 Billion Manufacturing Deal with Regeneron
April 23, 2025
-
BUSINESS Vital-Net Bags Japan Rights to Shield’s Iron Deficiency Med
April 23, 2025
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…